NEW YORK, Jan. 2, 2026 — Hoth Therapeutics (NASDAQ: HOTH) announced the filing of two U.S. provisional patent applications that expand its intellectual property and establish an oncology-focused dermatology platform targeting treatment-induced skin toxicity from modern cancer therapies.
One provisional application covers the topical treatment of radiation-induced skin toxicity in oncology patients. The other addresses dermatologic toxicities linked to emerging targeted cancer therapies, including second- and third-generation menin inhibitors. Together the filings seek priority rights for the use of HT-001 to treat skin toxicities across multiple oncology modalities.
As cancer treatments improve and patients remain on therapy longer, treatment-limiting skin toxicities have become a growing unmet need. Radiotherapy-induced dermatitis and adverse skin effects from targeted agents frequently cause pain, inflammation, severe pruritus, infection risk, reduced quality of life, and interruptions or discontinuations of cancer therapy. Current options are largely supportive and few therapies target underlying biological drivers.
Hoth says HT-001, a receptor antagonist with an established pharmacologic profile, is designed to target neurogenic and inflammatory pathways implicated in therapy-induced skin injury. The company believes this approach could represent a novel, potentially first-in-class strategy in oncology supportive care and oncodermatology.
“These filings represent a meaningful expansion of our intellectual property estate into an increasingly important area of oncology care,” said Robb Knie, CEO of Hoth Therapeutics. “As cancer therapies advance, the ability to manage treatment-related toxicities is becoming essential. We believe this emerging platform highlights our strategy of identifying differentiated, mechanism-driven opportunities that can address significant unmet needs while creating long-term shareholder value.”
Hoth says the provisional patents support development of a scalable oncology-adjacent platform with potential applications across radiation oncology, targeted cancer therapies, dermatology, and inflammatory skin disorders, while allowing further preclinical work, formulation optimization, and pursuit of U.S. and international patent protection.
Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to improve patient quality of life. The company advances early-stage drugs through preclinical and clinical testing in collaboration with scientists, clinicians, and key opinion leaders. More information is available at https://ir.hoththerapeutics.com/.
This release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those projected. Investors should review Hoth’s filings with the U.S. Securities and Exchange Commission for a discussion of factors that could affect outcomes.
Investor contact: LR Advisors LLC, [email protected], (678) 570-6791. Website: www.hoththerapeutics.com.
Leave a Reply